ROSIGLITAZONE MALEATE AND GLIMEPIRIDE (glimepiride; rosiglitazone maleate) by Teva is cells. Approved for type 2 diabetes mellitus ( ), type 1 diabetes mellitus, type 2 diabetes mellitus. First approved in 2016.
Drug data last refreshed Yesterday
cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
Worked on ROSIGLITAZONE MALEATE AND GLIMEPIRIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.